Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of hereditary angioedema
Humanistic burden and health-related quality of life
21 evidence topics · 19 sources
Burden of disease in adults: multinational survey
Multinational adult survey: treatment exposure and quality-of-life outcomes
| Measure | Reported result |
|---|---|
| Participants included | “260” |
| Participants using any long-term prophylaxis | “153 (58.8%)” |
| First-line prophylaxis among prophylaxis users, per study classification | “56/153 (36.6%)” |
| AE-QoL total score, mean ± SD | “42.9 ± 23.2” |
| Participants with AE-QoL total score ≥39 | “137 of 260 (52.7%)” |
| Moderate to severe anxiety by HADS | “69 (26.5%)” |
| Moderate to severe depression by HADS | “27 (10.4%)” |
Health-related quality of life, depression, and work productivity: US patient survey
“A total of 457 HAE patients responded to the survey (response rate, ∼19%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients reported significantly poorer health-related quality of life versus population norms, based on the SF-12 Physical Component Summary (mean, 43.7 versus 49.6; p < 0.001) and Mental Component Summary (mean, 42.6 versus 49.4; p < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“HAE patients also had higher mean HDI-SF scores than population norms (8.1 ± 6.5 versus 3.1 ± 3.0; p < 0.001), with 42.5% of HAE patients scoring >8.5, indicative of depressive symptomatology.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Productivity was also markedly impaired in all WPAI-GH categories, including 34% overall work impairment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Because of their most recent HAE attack, workers lost a mean of 3.3 days; students lost a mean of 1.9 days.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Anxiety and depression: health technology assessment background
Quality of life with subcutaneous prophylaxis compared with on-demand treatment alone: US patient survey
“The greatest improvement in QoL was seen in patients who used novel SC prophylactic therapies, with a 59.5% (p < 0.01) improvement in median impairment scores versus on-demand–only treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, patients who used novel SC prophylactic therapies reported a 77% reduction in the number of attacks each year when compared with those who used on-demand–only treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden despite current therapies: US adult survey
“A web-based survey was conducted from March to April 2025 among 100 US adults with HAE-C1INH currently receiving long-term prophylaxis and/or on-demand therapies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Even with treatment, 80% of respondents reported ≥1 HAE attack in the past year and 61% thought about HAE at least weekly.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mental health was the aspect that respondents felt was most impacted by HAE (54% of respondents), and 73% reported taking ≥2 measures to avoid attack triggers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Several concerns impacted the ability to reach normalization; lifetime use of medication was the most commonly reported concern (68% of respondents).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The greatest unmet needs associated with long-term prophylaxis were cost- and access-related.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Preferences for long-term prophylaxis and willingness to switch: US adult survey
“A total of 150 individuals completed the survey.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Respondents rated effectiveness in preventing attacks and reducing the severity of attacks as the most important LTP attributes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Route of administration and convenience were more than twice as important as dosing frequency.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals preferred oral daily therapy to biweekly (54% vs 46%) or monthly injections (54% vs 46%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most individuals (71%) were at least somewhat willing to switch LTP treatments in the next 6 months, particularly those whose HAE was not well controlled, were anxious about taking LTP, were burdened by treating their HAE, or preferred oral administration.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life during the last treated attack by time to on-demand treatment: US patient survey
“Patients with ≥1 HAE attack in the previous 3 months were recruited by the United States (US) HAE Association (HAEA) to complete an online survey.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 94 respondents were included in the Treated Cohort, and 20 were included in the Untreated Cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the Treated Cohort, the mean (SD) EQ-5D-5L index score was 0.849 (0.2) “Today” and 0.568 (0.3) “During the last treated attack” (Fig. 1A), with the latter score indicative of substantial impairment in HRQoL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (SD) index score was 0.667 (0.3) in patients who treated <1 h of attack onset and 0.504 (0.3) in those who treated 5 to < 8 h of attack onset (Fig. 1B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In terms of administration route, reductions in HRQoL and work productivity and increases in activity impairment were generally more pronounced among IV OD users than among SC OD users (mean EQ-5D-5L index score “During the last treated attack”: 0.480 vs 0.615).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Consistent with this, IV OD users took longer to administer treatment following attack onset than SC OD users (mean: 5.8 vs 2.8 h).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Funding for Outcomes Insights was provided by KalVista Pharmaceuticals (Cambridge, MA, USA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Work productivity and activity impairment after a treated attack: US patient survey
“Patients with ≥1 HAE attack in the previous 3 months were recruited by the United States (US) HAE Association (HAEA) to complete an online survey.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the Treated Cohort, the mean value for attack-related activity impairment was 38% (Fig. 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the 7 days following attack onset, the average rates of absenteeism (work missed due to HAE), presenteeism (impairment while working due to HAE), and overall work impairment were 15%, 35%, and 39%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For respondents with “Mild,” “Moderate,” and “Severe” attacks, the mean level of absenteeism was 5%, 16%, and 35%; the mean level of presenteeism was 29%, 32%, and 68%; and mean overall work impairment was 32%, 36%, and 75%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment-related anxiety and delay of on-demand treatment: US patient survey
“Patients with HAE (type I or II) aged 12 years or older with more than or equal to 1 treated (Treated Cohort) or untreated (Untreated Cohort) attack in the past 3 months were recruited by the US HAE Association.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the Treated Cohort (n = 94), of the 67% who reported treating their attack early, only 26% administered OD in less than 1 hour.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, 79% (n = 74) reported treatment-related anxiety, which correlated with treatment delay.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Time to treatment paralleled changes in attack severity (33% mild attacks treated in <1 hour vs 67% in ≥1 hour, progressed to moderate/severe) and mean duration (<1 hour: 0.7 day; >8 hours: 2.7 days).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Untreated attacks lasted a mean of 2.3 days.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Attack-related anxiety in a randomized on-demand treatment trial: KONFIDENT
“Participants in the randomised, double‐blind, phase 3 KONFIDENT trial (NCT05259917) treated attacks with sebetralstat 300 mg, 600 mg or placebo as early as possible after onset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The full analysis set included 264 attacks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 115 (44%) of the attacks were rated as inducing moderate‐to‐extreme anxiety (i.e., GA‐NRS ≥ 4) at treatment administration (Table 1 and Table S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Female sex, shorter time since HAE diagnosis and greater attack severity were associated with greater anxiety at treatment administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was sponsored by KalVista Pharmaceuticals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden of injectable on-demand treatment: US and UK patient and caregiver interviews
“The 25 study participants from the US and UK (17 patients; 8 caregivers), who completed the interview, highlighted emotional and logistical reasons for delaying or forgoing injectable on-demand treatment, including fear of needles, portability, and complexity of administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants reported a dislike of needles, pain associated with injection of the medicine, and the need to go to a hospital or medical center as treatment-related reasons for delaying or opting not to treat an attack.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The majority of participants (80%) reported not treating every attack; all participants described delaying treatment intentionally or unintentionally at least once.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All participants expressed interest in an oral on-demand treatment for reasons including portability, pain-free administration, and ability to treat attacks earlier.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study was supported by KalVista Pharmaceuticals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Carrying, delaying, and not treating attacks with on-demand treatment: US patient survey
“People living with HAE were recruited by the US Hereditary Angioedema Association (HAEA) to complete a 20-minute online survey between September 6, and October 19, 2022.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Respondents included 107 people with HAE, 80% female, 98% adults (≥ 18 years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most patients (63.6%) reported that they did not carry on-demand treatment at all times when away from home.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common reason for not carrying on-demand treatment when away from home was ‘prefer to treat at home’ (72.1%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 86% of respondents reported delaying on-demand treatment, despite recognizing the initial onset of an HAE attack and despite 97% of patients agreeing that it is important to recover quickly from an HAE attack.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On average, one of every five (20%) HAE attacks are untreated (24% amongst on-demand only patients; 15% amongst prophylaxis patients).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This work was sponsored by KalVista Pharmaceuticals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Administration-site adverse drug reactions with parenteral on-demand treatments: FDA Adverse Event Reporting System
“We searched the FAERS database from October 1, 2009, to March 31, 2022, for reports of all FDA-approved on-demand therapies for HAE: plasma-derived C1-inhibitor (pdC1-INH), ecallantide, icatibant, and recombinant C1-inhibitor (rhC1-INH).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The highest reported rates of administration-site ADRs per year were site pain (17.9 reports per year), site erythema (7.4 per year), and site swelling (6.7 per year).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Conclusion: Real-world data from FAERS were generally consistent with adverse events reported in clinical trials and suggest that patients experience substantial treatment burden associated with FDA-approved parenteral on-demand therapies for HAE attacks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“It should be noted that ADR rates are not exposure adjusted and are based on spontaneous reporting.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Utility weights during and between attacks: European patient survey mapped to EQ-5D
“Survey items that overlapped conceptually with the EuroQol 5-Dimensions (EQ-5D) domains (pain/discomfort, mobility, self-care, usual activities, and anxiety/depression) were manually crosswalked to the corresponding UK population-based EQ-5D utility weights.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, a total of 111 HAE-BOIS-Europe participants completed all selected survey items and thus allowed for computation of EQ-5D-based utilities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean utilities for an HAE attack and between attacks were 0.44 and 0.72, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Utilities for an acute attack were dependent on the severity of pain of the last attack (0.61 for no pain or mild pain, 0.47 for moderate pain, and 0.08 for severe pain).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Time trade-off utilities by attack location: general public valuation in England
“Members of the general public in England rated vignettes in TTO interviews, which included a visual analogue scale (VAS) component.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“TTO analysis was based on vignette valuation completed by 100 members of the general public.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The TTO values were as follows: attack-free, 0.783 (standard deviation [SD] 0.316); hand: 0.582 (SD 0.380); facial: 0.483 (SD 0.448); abdominal: 0.345 (SD 0.458); and laryngeal: 0.128 (SD 0.529).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was funded by BioCryst Pharmaceuticals, Inc.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Utility weights with and without attack symptoms drawn from the literature for an economic model
“Utility values were drawn from the literature” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“citing a utility of 0.51 when experiencing attack symptoms and 0.83 without symptoms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nonattack baseline utility and attack utility were implemented for effectiveness calculations; time to attack resolution was considered as well.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EQ-5D-5L utility and its decrement during an attack: Dutch patient survey
“Adult patients with HAE under treatment at the Dutch national center of reference completed a cross-sectional survey in 2021.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The response rate was 78% (69 of 88).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean quality of life in the entire sample was 30.99 as expressed by the AE-QoL and 0.873 as expressed by the EQ-5D-5L utility value.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Utilities dropped by 0.320 points during an angioedema attack.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Patient-defined attack severity and EQ-5D-5L by attack location: US qualitative study for economic evaluation
Physician-reported attainment of treatment goals: international physician survey
“Of 64 respondents from 32 countries, most (91%) had > 5 years of experience in managing HAE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 48% of respondents (n = 31/64) reported that < 50% of their patients had achieved the WAO/EAACI HAE treatment goals of total disease control and “normalization” of life at the time of the survey.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Burden of disease remains a challenge among patients, as reported by their physicians.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was funded by CSL Behring.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Attacks, on-demand treatment, anxiety, and depression: multinational patient survey
“We conducted a noninterventional, cross-sectional, web-based survey of patients with a self-reported diagnosis of HAE type 1/2 in Australia, Austria, Canada, France, Germany, Spain, Switzerland, and the United Kingdom to gain a comprehensive real-world understanding of the characteristics of HAE and its burden from the perspective of the patient.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 242 patients (67.4% female; mean [range] age 43.8 [18–92] years) completed the survey.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients reported a mean (SD) of 12.5 (14.1) attacks in the past 6 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most recent attack occurred within the past month in 79.7% of patients; most were of moderate severity, 6.6% affected the larynx, 21.9% lasted ≥ 3 days, and 76.4% were treated with on-demand medication.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moderate to severe anxiety and depression were reported in 38.0% and 17.4% of patients, respectively, as measured using the HADS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote